Results of a long-term, prospective study on complications of central venous catheter in pediatric patients with hematologic-oncologic diseases.
central venous catheter
chemotherapy
complications
pediatric malignancy
stem cell transplantation
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
11 Apr 2024
11 Apr 2024
Historique:
revised:
14
03
2024
received:
04
02
2024
accepted:
19
03
2024
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
Central venous catheter (CVC)-related complications remain a significant cause of morbidity in pediatric hematology-oncology. We prospectively surveyed the incidence of CVC-related complications in children with hematologic-oncologic diseases. Five-hundred-eighty-one CVCs were inserted in 421 patients from January 2010 to June 2022 (153,731 CVC days observation; follow-up data up to December 31, 2022). Overall, 671 complications were recorded (4.365/1000 CVC days): 49.7% malfunctions (1.88/1000 CVC days, 4.8% of CVC early removals), 23.9% bacteremia (0.90/1000, 15.1%), 19.6% mechanical complications (0.74/1000, 70.2%), 20.1% localized infections (0.76/1000, 17.1%), 0.5% thrombosis (0.02/1000, 33.3%). At multivariate analysis, risk factors for malfunction were Broviac-Hickman type of CVC (hazard ratio [HR] 2.5) or Port-a-cath (HR 3.4) or Proline (HR 4.3), p < .0001; for bacteremia double-lumen CVC (HR 3.2, p < .0001); for mechanical complications age at CVC insertion under median (HR 4.5, p < .0001) and Broviac-Hickman (HR 1.6) or Proline (HR 2.7), p = .01; finally for localized infections Broviac-Hickman (HR 2.9) or Proline (HR 4.4), p = .0001. The 2-year cumulative incidence of premature removal was 23.5%, and risk factors were age at CVC insertion under median (HR 2.4, p < .0001), Broviac-Hickman (HR 2.3) or Proline (HR 4.2), p < .0001. Premature removal occurs in approximately 20%-25% of long-term CVCs. A surveillance program has a fundamental role in identifying the risk factors for CVC complications and the areas of intervention to improve CVC management.
Sections du résumé
BACKGROUND
BACKGROUND
Central venous catheter (CVC)-related complications remain a significant cause of morbidity in pediatric hematology-oncology. We prospectively surveyed the incidence of CVC-related complications in children with hematologic-oncologic diseases.
PROCEDURE
METHODS
Five-hundred-eighty-one CVCs were inserted in 421 patients from January 2010 to June 2022 (153,731 CVC days observation; follow-up data up to December 31, 2022).
RESULTS
RESULTS
Overall, 671 complications were recorded (4.365/1000 CVC days): 49.7% malfunctions (1.88/1000 CVC days, 4.8% of CVC early removals), 23.9% bacteremia (0.90/1000, 15.1%), 19.6% mechanical complications (0.74/1000, 70.2%), 20.1% localized infections (0.76/1000, 17.1%), 0.5% thrombosis (0.02/1000, 33.3%). At multivariate analysis, risk factors for malfunction were Broviac-Hickman type of CVC (hazard ratio [HR] 2.5) or Port-a-cath (HR 3.4) or Proline (HR 4.3), p < .0001; for bacteremia double-lumen CVC (HR 3.2, p < .0001); for mechanical complications age at CVC insertion under median (HR 4.5, p < .0001) and Broviac-Hickman (HR 1.6) or Proline (HR 2.7), p = .01; finally for localized infections Broviac-Hickman (HR 2.9) or Proline (HR 4.4), p = .0001. The 2-year cumulative incidence of premature removal was 23.5%, and risk factors were age at CVC insertion under median (HR 2.4, p < .0001), Broviac-Hickman (HR 2.3) or Proline (HR 4.2), p < .0001.
CONCLUSIONS
CONCLUSIONS
Premature removal occurs in approximately 20%-25% of long-term CVCs. A surveillance program has a fundamental role in identifying the risk factors for CVC complications and the areas of intervention to improve CVC management.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e30990Informations de copyright
© 2024 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Cesaro S, Cavaliere M, Pegoraro A, Gamba P, Zadra N, Tridello G. A comprehensive approach to the prevention of central venous catheter complications: results of 10‐year prospective surveillance in pediatric hematology‐oncology patients. Ann Hematol. 2016;95(5):817‐825. doi:10.1007/S00277‐016‐2634‐X
Crocoli A, Pittiruti M. Special problems of venous access in oncology and hematology. In: Biasucci DG, Disma NM, Pittiruti M, eds. Vascular Access in Neonates and Children. Springer; 2022. doi:10.1007/978‐3‐030‐94709‐5_25
Cellini M, Bergadano A, Crocoli A, et al. Guidelines of the Italian Association of Pediatric Hematology and Oncology for the management of the central venous access devices in pediatric patients with onco‐hematological disease. J Vasc Access. 2022;23(1):3‐17. doi:10.1177/1129729820969309
Cesaro S, Minniti F. Vascular access. In: Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. Springer International Publishing; 2019. doi:10.1007/978‐3‐030‐02278‐5_22
Buchanan C, Burt A, Moureau N, Murray D, Nizum N. Registered Nurses’ Association of Ontario (RNAO) best practice guideline on the assessment and management of vascular access devices. J Vasc Access. 2023. doi:10.1177/11297298231169468
ISO 9001:2015 – Quality management systems. ISO. Accessed November 6, 2023. https://www.iso.org/standard/62085.html
Pittiruti M, Scoppettuolo G. Raccomandazioni GAVeCeLT 2021 per la indicazione, l'impianto e la gestione dei dispositivi per l'accesso venoso. GAVeCeLT; 2021. Accessed November 6, 2023. https://gavecelt.it/nuovo/sites/default/files/uploads/Raccomandazioni%20GAVeCeLT%202021%20‐%20v.2.0.pdf
Center for Disease Control and Prevention. Bloodstream infection event (central line‐associated bloodstream infection and non‐central line associated bloodstream infection). Center for Disease Control and Prevention; August 2023. Accessed November 6, 2023. https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf
Beck O, Muensterer O, Hofmann S, et al. Central venous access devices (CVAD) in pediatric oncology patients—a single‐center retrospective study over more than 9 years. Front Pediatr. 2019;7:260. doi:10.3389/FPED.2019.00260
Revel‐Vilk S, Yacobovich J, Tamary H, et al. Risk factors for central venous catheter thrombotic complications in children and adolescents with cancer. Cancer. 2010;116(17):4197‐4205. doi:10.1002/CNCR.25199
van den Bosch CH, van der Bruggen JT, Frakking FNJ, et al. Incidence, severity and outcome of central line related complications in pediatric oncology patients; a single center study. J Pediatr Surg. 2019;54(9):1894‐1900. doi:10.1016/J.JPEDSURG.2018.10.054
Agrawal SK, Gautam H, Choudhary AH, Das BK, Kumar L, Kapil A. Central line‐associated bloodstream infections in cancer patients: an experience from a tertiary care cancer centre. Indian J Med Microbiol. 2019;37(3):376‐380. doi:10.4103/IJMM.IJMM_19_352
Celebi S, Sezgin ME, Cakir D, et al. Catheter‐associated bloodstream infections in pediatric hematology‐oncology patients. Pediatr Hematol Oncol. 2013;30(3):187‐194. doi:10.3109/08880018.2013.772683
Kelada AS, Foster TB, Gagliano GC, et al. Central‐line‐associated bloodstream infections and central‐line‐associated non‐CLABSI complications among pediatric oncology patients. Infect Control Hosp Epidemiol. 2023;44(3):377‐383. doi:10.1017/ICE.2022.91
Handrup MM, Møller JK, Frydenberg M, Schrøder H. Placing of tunneled central venous catheters prior to induction chemotherapy in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2010;55(2):309‐313. doi:10.1002/PBC.22530
Ruggiero A, Barone G, Margani G, Nanni L, Pittiruti M, Riccardi R. Groshong catheter‐related complications in children with cancer. Pediatr Blood Cancer. 2010;54(7):947‐951. doi:10.1002/PBC.22416
Pektaş A, Kara A, Gurgey A. Cohort study: central venous catheter‐related complications in children with hematologic diseases at a single center. Turk J Haematol. 2015;32(2):144‐151. doi:10.4274/TJH.2013.0403
Crocoli A, Martucci C, Sidro L, et al. Safety and effectiveness of subcutaneously anchored securement for tunneled central catheters in oncological pediatric patients: a retrospective study. J Vasc Access. 2023;24(1):35‐40. doi:10.1177/11297298211009364